Verrica Pharmaceuticals Inc. (VRCA)

NASDAQ: VRCA · IEX Real-Time Price · USD
2.65
+0.07 (2.71%)
At close: Nov 29, 2022 4:00 PM
2.78
+0.13 (4.91%)
After-hours: Nov 29, 2022 4:39 PM EST
2.71%
Market Cap 106.02M
Revenue (ttm) 8.96M
Net Income (ttm) -28.10M
Shares Out 40.30M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,316
Open 2.62
Previous Close 2.58
Day's Range 2.6 - 2.78
52-Week Range 1.77 - 10.98
Beta 1.93
Analysts Buy
Price Target 11.83 (+346.4%)
Earnings Date Nov 11, 2022

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agr... [Read more]

Industry Pharmaceuticals
IPO Date Jun 15, 2018
CEO Ted White
Employees 38
Stock Exchange NASDAQ
Ticker Symbol VRCA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VRCA stock is "Buy." The 12-month stock price forecast is 11.83, which is an increase of 346.42% from the latest price.

Price Target
$11.83
(346.42% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023

3 weeks ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

2 months ago - GlobeNewsWire

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum

3 months ago - GlobeNewsWire

VRCA SHAREHOLDER ALERT: Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

NEW YORK , Aug. 5, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA). To ...

3 months ago - PRNewsWire

VRCA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors to Secure Cou...

New York, New York--(Newsfile Corp. - August 5, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) betwee...

3 months ago - Newsfile Corp

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to C...

Los Angeles, California--(Newsfile Corp. - August 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceutica...

3 months ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Ph...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...

3 months ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,...

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

3 months ago - Business Wire

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 t...

Los Angeles, California--(Newsfile Corp. - August 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceutica...

3 months ago - Newsfile Corp

VRCA LAWSUIT ALERT: Levi & Korsinsky Notifies Verrica Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and U...

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Verrica Pharmaceuticals, Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) of a class action securities lawsuit. CLASS ...

3 months ago - PRNewsWire

Verrica Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 5, 2022 to Discuss Your...

New York, New York--(Newsfile Corp. - August 3, 2022) - Levi & Korsinsky, LLP notifies investors in Verrica Pharmaceuticals, Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) of a class action securities...

3 months ago - Newsfile Corp

FRIDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,...

Los Angeles, California--(Newsfile Corp. - August 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceutica...

3 months ago - Newsfile Corp

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000...

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

3 months ago - Business Wire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Verrica Pharmaceuticals, Inc. of a Class Action Lawsui...

NEW YORK , Aug. 3, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Verrica Pharmaceuticals, Inc.. Shareholders who purchased shares of VRCA during the class period...

3 months ago - PRNewsWire

VRCA Investors Have Opportunity to Lead Verrica Pharmaceuticals Inc. Securities Fraud Lawsuit

LOS ANGELES , Aug. 2, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ve...

3 months ago - PRNewsWire

FRIDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $10...

Los Angeles, California--(Newsfile Corp. - August 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceutica...

3 months ago - Newsfile Corp

VRCA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 5, 2022 in the Class Action Filed on Beh...

NEW YORK , Aug. 2, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) alleging that ...

3 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals, Inc. -VRCA

NEW YORK , Aug. 1, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals, Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such investors are advi...

3 months ago - PRNewsWire

Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Tori...

The Company earns $8 Million Phase 3 Milestone Payment

3 months ago - GlobeNewsWire

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Verrica Investors of a Lead Plaintiff Deadline of August 5...

NEW YORK , Aug. 1, 2022 /PRNewswire/ -- Attention Verrica Pharmaceuticals, Inc. ("Verrica") (NASDAQ: VRCA) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commence...

3 months ago - PRNewsWire

VRCA INVESTOR NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors w...

NEW YORK , July 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 ...

3 months ago - PRNewsWire

ROSEN, Leading Investor Counsel, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Befo...

New York, New York--(Newsfile Corp. - July 28, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between...

4 months ago - Newsfile Corp

Verrica Class Action: Levi & Korsinsky Reminds Verrica Pharmaceuticals, Inc. Investors of the Pending Class Action La...

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky, LLP notifies investors in Verrica Pharmaceuticals, Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) of a class action securities ...

4 months ago - Newsfile Corp

ROSEN, National Trial Lawyers, Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before...

New York, New York--(Newsfile Corp. - July 27, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between...

4 months ago - Newsfile Corp

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,0...

Los Angeles, California--(Newsfile Corp. - July 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceutical...

4 months ago - Newsfile Corp